Value202320242025TTMSelling/general/admin expenses811 M618 M634 M634 MResearch & development106 M108 M97 M97 MOperating income4 M32 M262 M262 MNon-Operating Income, Total—25 M23 M23 MInterest expense, net of interest capitalized—35 M43 M43 MNon-Operating Income, excl. Interest Expenses—-10 M-20 M-20 MUnusual income/expense————Pretax income1 M14 M239 M239 MEquity in earnings————Taxes1 M11 M29 M29 MNon-controlling/minority interest————After tax other income/expense—0——Net income before discontinued operations2 M2 M210 M210 MDiscontinued operations————Net income2 M2 M210 M210 MDilution adjustment————Preferred dividends————Diluted net income available to common stockholders—2 M210 M210 MBasic earnings per share (Basic EPS)—0.021.681.68Diluted earnings per share (Diluted EPS)—0.021.641.64Average basic shares outstanding—132 M125 M499 MDiluted shares outstanding—133 M128 M508 MEBITDA—61 M723 M270 MEBIT—32 M713 M260 MCost of revenue186 M231 M246 M246 MOther cost of goods sold—36 M26 M—Depreciation & amortization (cash flow)17 M29 M10 M10 M
Indivior Pharmaceuticals Inc
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.